Shire Viropharma Stock Price, News & Analysis (NASDAQ:VPHM)

Previous CloseN/A
Today's RangeN/A
52-Week Range$23.13 - $50.01
VolumeN/A
Average VolumeN/A
Market Capitalization$3.3 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14

About Shire Viropharma (NASDAQ:VPHM)

Shire Viropharma logoViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Pharmaceuticals
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:VPHM
  • CUSIP: 92824110
  • Web: www.viropharma.com
Misc:
  • Outstanding Shares: 65,860,000
 

Frequently Asked Questions for Shire Viropharma (NASDAQ:VPHM)

What is Shire Viropharma's stock symbol?

Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."

How were Shire Viropharma's earnings last quarter?

Shire Viropharma Inc (NASDAQ:VPHM) posted its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.05 by $0.15. The biotechnology company had revenue of $113 million for the quarter, compared to analysts' expectations of $113.35 million. The firm's revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. View Shire Viropharma's Earnings History.

Who are some of Shire Viropharma's key competitors?

How do I buy Shire Viropharma stock?

Shares of Shire Viropharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire Viropharma?

Shire Viropharma has a market capitalization of $3.3 billion.

How can I contact Shire Viropharma?

Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.


MarketBeat Community Rating for Shire Viropharma (NASDAQ VPHM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  294
MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Shire Viropharma (NASDAQ:VPHM)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Shire Viropharma (NASDAQ:VPHM)

Price Target History for Shire Viropharma (NASDAQ:VPHM)

Analysts' Ratings History for Shire Viropharma (NASDAQ:VPHM)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for Shire Viropharma (NASDAQ:VPHM)

Earnings by Quarter for Shire Viropharma (NASDAQ:VPHM)

Earnings History by Quarter for Shire Viropharma (NASDAQ VPHM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2013Q313$0.05$0.20$113.35 million$113.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.15$105.06 million$104.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.04$0.15$108.47 million$107.00 millionViewN/AView Earnings Details
2/27/2013Q4 2012$0.03$0.10$103.06 million$106.50 millionViewN/AView Earnings Details
10/25/2012$0.13$0.10ViewN/AView Earnings Details
8/9/2012$0.19$0.09ViewN/AView Earnings Details
5/1/2012$0.42$0.37ViewN/AView Earnings Details
2/28/2012$0.44$0.65ViewN/AView Earnings Details
10/27/2011$0.37$0.56ViewN/AView Earnings Details
7/28/2011$0.41$0.28ViewN/AView Earnings Details
4/28/2011$0.41$0.40ViewN/AView Earnings Details
2/24/2011$0.32$0.43ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Shire Viropharma (NASDAQ:VPHM)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Shire Viropharma (NASDAQ:VPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Shire Viropharma (NASDAQ VPHM)

Insider Trades by Quarter for Shire Viropharma (NASDAQ:VPHM)

Insider Trades by Quarter for Shire Viropharma (NASDAQ VPHM)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/24/2012Colin Md BroomVPSell17,500$22.53$394,275.00View SEC Filing  
12/3/2012John Peter Wolf IIIVPSell18,000$24.85$447,300.00View SEC Filing  
12/3/2012William D Md ClaypoolDirectorSell10,000$24.80$248,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Shire Viropharma (NASDAQ:VPHM)

Latest Headlines for Shire Viropharma (NASDAQ VPHM)

Source:
DateHeadline
Critical Review: Adamis Pharmaceuticals Corporation (ADMP) and Shire Viropharma (VPHM)Critical Review: Adamis Pharmaceuticals Corporation (ADMP) and Shire Viropharma (VPHM)
www.americanbankingnews.com - October 14 at 10:46 AM
Contrasting Shire Viropharma (VPHM) & BioLife Solutions (BLFS)Contrasting Shire Viropharma (VPHM) & BioLife Solutions (BLFS)
www.americanbankingnews.com - September 12 at 2:26 AM
Comparing Eli Lilly and (LLY) & Shire Viropharma (VPHM)Comparing Eli Lilly and (LLY) & Shire Viropharma (VPHM)
www.americanbankingnews.com - September 9 at 6:22 PM
Promising New Treatment Emerges For Deadly C. difficile ColitisPromising New Treatment Emerges For Deadly C. difficile Colitis
www.forbes.com - May 5 at 11:00 AM

Social Media

Financials

Chart

Shire Viropharma (NASDAQ VPHM) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.